- Home
- GABC vs TSHA Comparison
GABC vs TSHA Comparison
Compare GABC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GABC
- TSHA
- Stock Information
- Founded
- GABC 1910
- TSHA 2019
- Country
- GABC United States
- TSHA United States
- Employees
- GABC N/A
- TSHA N/A
- Industry
- GABC Major Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- GABC Finance
- TSHA Health Care
- Exchange
- GABC Nasdaq
- TSHA Nasdaq
- Market Cap
- GABC 1.5B
- TSHA 1.4B
- IPO Year
- GABC N/A
- TSHA 2020
- Fundamental
- Price
- GABC $39.58
- TSHA $3.84
- Analyst Decision
- GABC Hold
- TSHA Strong Buy
- Analyst Count
- GABC 2
- TSHA 9
- Target Price
- GABC $45.50
- TSHA $10.22
- AVG Volume (30 Days)
- GABC 95.3K
- TSHA 4.2M
- Earning Date
- GABC 10-27-2025
- TSHA 11-04-2025
- Dividend Yield
- GABC 2.92%
- TSHA N/A
- EPS Growth
- GABC 3.79
- TSHA N/A
- EPS
- GABC 2.87
- TSHA N/A
- Revenue
- GABC $312,775,000.00
- TSHA $6,310,000.00
- Revenue This Year
- GABC $47.67
- TSHA N/A
- Revenue Next Year
- GABC $6.23
- TSHA N/A
- P/E Ratio
- GABC $13.80
- TSHA N/A
- Revenue Growth
- GABC 26.89
- TSHA N/A
- 52 Week Low
- GABC $32.75
- TSHA $1.05
- 52 Week High
- GABC $47.08
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- GABC 52.00
- TSHA 37.78
- Support Level
- GABC $38.10
- TSHA $3.89
- Resistance Level
- GABC $39.96
- TSHA $4.55
- Average True Range (ATR)
- GABC 0.79
- TSHA 0.39
- MACD
- GABC 0.12
- TSHA -0.19
- Stochastic Oscillator
- GABC 50.76
- TSHA 8.99
About GABC German American Bancorp Inc.
German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.